The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis transmembrane conductance regulator (CFTR) modulators. 1 BI 3720931 is a first-in-class, inhaled ...

Cystic fibrosis (CF) is common ... have issues with subfertility or infertility. CFTR modulators have transformed the lives of pwCF who have the specific genetic variants that respond to the treatment ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ... some people with CF respond well to relatively new treatments known as CFTR ...

The trial specifically focuses on adults with CF who genetically cannot benefit from cystic fibrosis transmembrane conductance ... on the specific mutations that have occurred.[ii] Treatment with CFTR ...

A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows ... The scientists noted more work will be needed to develop treatment ...

The aim is to improve lung function and reduce exacerbations for people with CF irrespective of their mutations, including those who genetically cannot benefit from CFTR modulators ... and effective ...

While the immediate target are those adult patients who are not eligible for CFTR modulators ... rates of diagnosis and effective treatment for cystic fibrosis. J. Cyst. Fibros.

and efficacy of BI 3720931 in adults with cystic fibrosis, who are not eligible for CFTR modulator therapy. The trial has two parts. In the Phase I-part, different doses of the treatment will be ...